Dechra Launches New Single-dose Solution For BRD – Cyclofin
3 months ago 
496 views
Dechra has launched Cyclofin, a fast-acting, injectable single-dose solution for acute bovine respiratory disease (BRD) caused by oxytetracycline sensitive Mannheimia (Pasteurella) haemolytica and Pasteurella multocida where an anti-inflammatory and anti-pyretic effect is required.
Cyclofin has proven efficacy in treating BRD and is a convenient, single-dose injectable combining two actives: flunixin-meglumine 200 mg/ml (eq. to 33.2 mg/ml flunixin meglumine) is a potent and trusted anti-inflammatory, while oxytetracycline 300 mg/ml (eq. to 323.5 mg/ml oxytetracycline trihydrate) is a first choice anti-infective (class D). Cylofin acts within 24-36 hours and has sustained anti-bacterial activity for five to six days following a single intramuscular injection.
Administration is deep intramuscular injection in cattle and Cyclofin has a 35-day withdrawal period and a memorable dose rate of 1 ml per 10 kg body weight. It is both convenient to use on farm and is good value for farm vets.
Alana McGlade MRCVS, national sales manager at Dechra, comments: “BRD is one of the most prevalent and costly diseases on farm and early administration of an effective and fast-acting NSAID/antibiotic combination treatment, such as Cyclofin, can help relieve discomfort and stress, alleviate pain and improve demeanour and food intake.”
Cyclofin is available in 100ml vials. For further information on Cyclofin, visit https://www.dechra.co.uk/products/livestock/prescription/cyclofin#Cyclofin-300mg-ml or contact your local Dechra key account manager.
More from Dechra
- Vaccination key to offering BEST protection against strangles!
- Dechra wins Integrated Digital Campaign Award at VMA Awards
- Dechra launches new PPID treatment, Pergocoat
- Dechra sponsors sessions at Virtual Veterinary Conference 2024
- Vet nurses ‘on cloud nine’ after winning £250 Virgin Experience Days gift cards at LVS
2 days ago